Illumina, Inc. is a leading developer, manufacturer and marketer of life science tools and integrated systems for large‐scale analysis of genetic variation and function. Founded in 1998 and headquartered in San Diego, California, the company pioneered next-generation sequencing (NGS) technology that has accelerated research in genomics and transformed applications in diagnostics, agriculture and drug development. Its flagship platforms include the NovaSeq, NextSeq and MiSeq systems, which enable high-throughput sequencing for whole-genome, exome and targeted panels.
In addition to sequencing instruments, Illumina offers a broad portfolio of microarray products, consumables, software and services designed to support diverse workflows from sample preparation through data analysis. The company’s reagent kits and flow cells ensure high accuracy and reproducibility, while its BaseSpace Sequence Hub provides a cloud-based environment for data management, secondary analysis and collaboration. These integrated solutions serve customers in academic institutions, clinical laboratories, pharmaceutical companies and agricultural research centers worldwide.
Illumina’s technologies have underpinned major scientific projects such as the Human Genome Project follow-on studies, large-scale population genomics initiatives and precision medicine programs. By enabling rapid, cost-effective genomic data generation, the company has opened new avenues in oncology, prenatal testing, rare disease research and microbial genomics. Collaborations with leading healthcare providers and research consortia further extend the reach of its diagnostic and therapeutic applications.
Governed by a seasoned leadership team and board of directors, Illumina is led by President and Chief Executive Officer Francis deSouza, who has guided the company through significant product launches and strategic partnerships. With operational centers in North America, Europe and Asia-Pacific, Illumina maintains a global footprint that supports local market needs while fostering innovation through regional R&D hubs. The company continues to invest in expanding its technological capabilities to address emerging challenges in genomics and personalized medicine.
AI Generated. May Contain Errors.